160 related articles for article (PubMed ID: 32801292)
1. Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass.
Yu XP; Liu Y; Jiao JW; Yang HJ; Wang RJ; Zhang S
Med Sci Monit; 2020 Aug; 26():e924497. PubMed ID: 32801292
[TBL] [Abstract][Full Text] [Related]
2. MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors.
Yu XP; Wang L; Yu HY; Zou YW; Wang C; Jiao JW; Hong H; Zhang S
Cancer Manag Res; 2021; 13():329-336. PubMed ID: 33488120
[TBL] [Abstract][Full Text] [Related]
3. Radiomics nomogram for preoperative differentiation of early-stage serous borderline ovarian tumors and serous malignant ovarian tumors.
Yu X; Zou Y; Wang L; Yang H; Jiao J; Yu H; Zhang S
Front Oncol; 2023; 13():1269589. PubMed ID: 38288103
[TBL] [Abstract][Full Text] [Related]
4. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors.
Xiao F; Zhang L; Yang S; Peng K; Hua T; Tang G
J Ovarian Res; 2022 Jan; 15(1):13. PubMed ID: 35062992
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
7. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
Yu N; Wang N; Liu YF; Li YY; Zhang TG
Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of ovarian cancers from borderline ovarian tumors on the basis of evaluation of tumor vascularity in multi-row detector computed tomography--comparison with histopathology.
Grabowska-Derlatka L; Derlatka P; Palczewski P; Danska-Bidzinska A; Pacho R
Int J Gynecol Cancer; 2013 Nov; 23(9):1597-602. PubMed ID: 24172096
[TBL] [Abstract][Full Text] [Related]
11. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
Saygili U; Uslu T; Erten O; Doğan E
Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
[TBL] [Abstract][Full Text] [Related]
12. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
13. Perfusion-based functional magnetic resonance imaging for differentiating serous borderline ovarian tumors from early serous ovarian cancers in a rat model.
Cai SQ; Li Y; Li YA; Wang L; Zhu J; Zhao SH; Qiang JW
Acta Radiol; 2021 Jan; 62(1):129-138. PubMed ID: 32276553
[TBL] [Abstract][Full Text] [Related]
14. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
15. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
17. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Zhang W; Wang L; Xin Z
Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
[TBL] [Abstract][Full Text] [Related]
18. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
19. Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma: Evaluation of tumour markers and "mille-feuille sign" on computed tomography/magnetic resonance imaging.
Kurokawa R; Nakai Y; Gonoi W; Mori H; Tsuruga T; Makise N; Ushiku T; Abe O
Eur J Radiol; 2020 Mar; 124():108823. PubMed ID: 31935596
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.
Chen YN; Ma F; Zhang YD; Chen L; Li CY; Gong SP
Curr Med Sci; 2020 Feb; 40(1):184-191. PubMed ID: 32166682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
